Lupin Limited (NSE:LUPIN)
1,995.20
-4.40 (-0.22%)
Jun 9, 2025, 3:29 PM IST
Lupin Revenue
In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B INR with 13.48% growth. Lupin had revenue of 56.67B in the quarter ending March 31, 2025, with 14.24% growth.
Revenue
227.08B
Revenue Growth
+13.48%
P/S Ratio
4.02
Revenue / Employee
11.82M
Employees
19,210
Market Cap
913.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 525.78B |
Divi's Laboratories | 93.60B |
Cipla | 271.45B |
Apollo Hospitals Enterprise | 217.94B |
Mankind Pharma | 122.07B |
Zydus Lifesciences | 232.42B |
Aurobindo Pharma | 317.24B |
Alkem Laboratories | 129.65B |
Lupin News
- 2 days ago - Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets - Business Upturn
- 13 days ago - Lupin to present Phase 1 data on LNP7457 cancer drug at ASCO 2025 - Business Upturn
- 14 days ago - Lupin and SteinCares sign license and supply agreement for Ranibizumab in Latin America - Business Upturn
- 25 days ago - Lupin secures FDA approval for Rivaroxaban 10 mg, 15 mg and 20 mg tablets - Business Upturn
- 27 days ago - Lupin launches Tolvaptan tablets in the US for ADPKD treatment - Business Upturn
- 4 weeks ago - Lupin launches Eslicarbazepine Acetate Tablets in the US - Business Upturn
- 5 weeks ago - Lupin extends slump sale of API R&D and OTC business to June 30, 2025 - Business Upturn
- 6 weeks ago - Lupin receives U.S. FDA approval for Tolvaptan tablets with 180-day exclusivity - Business Upturn